NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
NASDAQ: NAMS · Pharmaceutical Preparations · Narrden, P7
Our rating: Cautious
Cautious reaffirmed at $27.83, moderate conviction, August 12, 2026.
Breaks if: The Cautious view would be wrong if the FDA approves obicetrapib with a label covering a broad LDL-lowering indication within 12 months of today, or if the company announces a new commercial or licensing partnership carrying at least $150M in upfront payments within the next two quarters — either event would demonstrate that the pipeline value embedded in the price is converting into clinical and commercial reality rather than remaining speculative, which would warrant a reassessment toward Positive.
Key figures
| Market value | $2.2B |
|---|---|
| Revenue, last 12 months | $26M |
| Net income, last 12 months | −$205M |
| Free cash flow, last 12 months | −$151M |
| Price to earnings | n/a |
| Free cash flow yield | −6.8% |
| Dividend yield | 0.0% |
| Operating margin | −900.1% |
| Return on equity | −30.2% |
| Beta to the S&P 500 | 1.08 |
| Volatility, annualized | 61.2% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $19M | 5406.9% | $-0.14 | −$40M |
| June 30, 2026 | $4M | −80.7% | $-0.52 | −$39M |
| March 31, 2026 | $3M | 2.1% | $-0.40 | −$31M |
| December 31, 2025 | $32000.00 | −99.7% | $-0.63 | −$41M |
| September 30, 2025 | $348000.00 | −98.8% | $-0.61 | −$33M |
| June 30, 2025 | $19M | 740.1% | $-0.15 | −$38M |
| March 31, 2025 | $3M | 112.6% | $-0.34 | −$36M |
| December 31, 2024 | $13M | 1490.5% | $-0.95 | −$37M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.00B: Claude 85%, Gemini 99%, Mistral 99%
- Diluted earnings per share are above zero: Claude 4%, Gemini 5%, Mistral 5%
- Free cash flow for the quarter is above zero: Claude 8%, Gemini 5%, Mistral 5%
12 ledger entries and 13 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.